Disease · MONDO_0006629

osteoarthritis, hip

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. osteoarthritis, hip. Diseases, record MONDO_0006629. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006629

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: osteoarthritis, hip; Open Targets
Open Targets ID: MONDO_0006629; Open Targets
Other names: Coxarthroses, Coxarthrosis, Hip Osteoarthritides, Osteoarthritides, Hip, Osteoarthritis Of Hip, Osteoarthritis Of Hips, hip osteoarthritis, osteoarthritis of the hip; Open Targets
MeSH: D015207; MeSH
NCI Thesaurus: C34876; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 6 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ACETAMINOPHEN	CHEMBL112	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
HYALURONIC ACID	CHEMBL5314376		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FASINUMAB	CHEMBL2109528	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HYALURONATE SODIUM	CHEMBL4594244		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TIGECYCLINE	CHEMBL376140	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CLONIDINE	CHEMBL134	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVOBUPIVACAINE	CHEMBL1201193	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN4A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6329	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
SCN10A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6328	Drugs and targets
SCN5A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6331	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02683239	Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip	Phase 3	5,331	2023-10-13	Osteoarthritis of the Knee or Hip	FASINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03793010	Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis	Phase 3	70	2020-09-14	Osteoarthritis, Hip	TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT00240773	A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee	Phase 3	581		Osteoarthritis, Hip, Osteoarthritis, Knee	ACETAMINOPHEN, NAPROXEN	Its record names the disease	ClinicalTrials.gov
NCT00240799	An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.	Phase 3	542		Osteoarthritis	ACETAMINOPHEN	Its record names the disease	ClinicalTrials.gov
NCT06230081	Comparison Between Blocks or Not in Joint Arthroplasty	Not applicable	400		Osteoarthritis of the Knee or Hip	CLONIDINE, ROPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT04438265	Quadratus Lumborum Type 2 as Chronic Hip Pain Treatment		200		Hip Arthropathy, Chronic Hip Pain, Ultrasound Therapy; Complications	LEVOBUPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT00330135	The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis	Phase 3	85		Symptomatic Hip Osteoarthritis	HYALURONATE SODIUM, HYALURONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02694146	Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis	Phase 3	74		Coxarthrosis	HYALURONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT06034418	Efficacy of Pulse Radiofrequency Treatment in Patients With Coxarthrosis	Not applicable	28		Coxarthrosis; Primary	BETAMETHASONE, LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT06977568	A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip	Phase 2	1		Osteoarthritis of Hip	TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
FX006 vs Normal Saline: deaths from any cause	0 of 33	0 of 35	68	NCT03793010	Trial comparisons
FX006 vs Normal Saline: serious adverse events	0 of 33	0 of 35	68	NCT03793010	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36282230	RESULT	1	PubMed
41545313	DERIVED	1	PubMed
40214220	DERIVED	1	PubMed
39004211	DERIVED	1	PubMed
25121804	DERIVED	1	PubMed
19248105	DERIVED	1	PubMed
17076974	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006629

GET https://conductscience.org/api/diseases/v1/MONDO_0006629/drugs

API reference For AI assistants